Real-Life Effectiveness and Safety of Baricitinib in Adults with Alopecia Areata: A Multicenter Study

    March 2025 in “ Journal of the European Academy of Dermatology and Venereology ”
    A Mourtada, C. Douarec, Matthieu Wargny, V. Hébert, Z. Reguiaï, P. Joly, Julien Séneschal, C. Toussaint, H. Aubert, M. Le Moigne, C. Bernier, Thierry Passeron, C. Jacobzone Leveque, Pascal Reygagne, S. Le Naour, C. Berthin, C. Bara, Maxime Fouchard, R. Janela‐Lapert, M. Masson Regnault, M.B. Duval, M. Jachiet, M. Fenot, H. Adamski, Marie-Emeline Marniquet, S. Barbarot
    TLDR Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
    This multicentre study involving 99 adult patients with alopecia areata (AA) across 13 centers found that baricitinib, at a dosage of 4 mg per day, was effective in reducing hair loss, with 75.5% of patients achieving a SALT50 response at 12 months. Patients with an initial SALT score <50 and those receiving baricitinib with systemic corticosteroids showed a higher likelihood of a good response. Adverse events occurred in 21.1% of patients, with acneiform rash being the most common, but no severe adverse events were reported. The study concludes that baricitinib is a well-tolerated and effective treatment for AA, even in refractory cases, though larger studies are needed to evaluate long-term safety and effects of treatment withdrawal.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results

    Related Community Posts Join

    6 / 12 results

    Related Research

    1 / 1 results